Plenty of drugmakers, including Shire and J&J, market ADHD drugs for children. But those drugs may not help kids do their homework or get better grades, a…

You know that old saw about every med school graduate winning the “Doctor” title? Something similar could apply to Sarepta’s newly approved Duchenne muscular…

Pfizer’s vaccines business has enjoyed tremendous growth, thanks to the superstar pneumococcal blocker Prevnar 13. But that growth could be tough to sustain,…

Every race car driver has sponsors. But not every sponsor gets the articulate marketing backup that Indy driver Charlie Kimball, who has Type 1 diabetes,…

McCann Health has launched a new consultancy, Consulting at McCann Health, with two objectives. The first: consolidate its health consulting agencies. And the…

When Gilead's hep C drugs hit the market, their older rivals went into a tailspin. Now, it's Gilead's time to suffer. The hep C market is once…

The list of drugmakers reportedly eying Bayer’s up-for-sale dermatology unit is growing even longer.

Bad news for Amgen’s first-line Kyprolis ambitions: The med has flopped in its first Phase III study in newly diagnosed multiple myeloma patients.